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Drug resistance in bacterial infections and cancers constitutes a major threat to human 
health. Treatments often include several interacting drugs, but even potent therapies can 
become ineffective in resistant mutants. Here we simplify the picture of drug resistance 
by identifying scaling laws that unify the multi-drug responses of drug sensitive and drug 
resistant cells. Based on these scaling relationships, we are able to infer the two-drug 
response  of  resistant  mutants  in  previously  unsampled  regions  of  dosage  space  in 
clinically relevant microbes such as E. coli, E. faecalis, S. aureus and S. cerevisiae, as 
well as in human non-small cell lung cancer, melanoma, and breast cancer stem cells. 
Importantly, we find that scaling relations also apply across evolutionarily close strains. 
Finally, scaling allows one to rapidly identify new drug combinations and predict potent 
dosage regimes for targeting resistant mutants without any prior mechanistic knowledge 
of the specific resistance mechanism. 
 
Main Text 
 
Introduction 
Treatment strategies for infectious diseases and cancers often involve multiple drugs that 
must be combined, adapted, and refined to target evolving cell populations. Multi-drug 
therapies can be difficult to design because drugs often interact, making their combined 
effects  larger  or  smaller  than  expected  from  their  individual  effects  (Bliss,  1956; 
Fitzgerald et al., 2006; Greco et al., 1995; Keith et al., 2005; Lehar et al., 2008; Loewe, 
1953). Furthermore, well-developed multi-drug treatments can be thwarted due to the 2 
 
emergence of multi-drug resistance, which arises in both bacterial infections and cancer 
and represents a growing public health threat (Levy and Marshall, 2004).  For example, 
potent drug regimens designed to target a particular cancer may be rendered ineffective 
by  the  rapid  evolution  of  drug-resistance  (Garrett  and  Arteaga,  2011;  Glickman  and 
Sawyers, 2012; Poulikakos and Rosen, 2011).  In addition, drugs may interact differently 
in each new resistant mutant, making the molecular characterization of resistance a time-
consuming and at times an untenable goal. Because of the rapidly increasing number of 
multi-drug resistant mutants, there is significant need for new strategies to characterize 
and refine drug regimens in hopes of mitigating the effects of resistance. 
 
Scaling laws can offer a complementary approach for simplifying the picture of multi-
drug-resistance  without  relying  on  highly  time-  and  resource-consuming  molecular 
studies. These laws—which can be surprisingly simple—are often based on symmetry 
arguments rather than system-specific microscopic details. Scaling is powerful because it 
offers a quantitative unifying framework for systems that appear, on the surface, to be 
very  different.   For  example,  allometric  scaling  laws  (Shoval  et  al.,  2012)  connect 
anatomical and physiological features, such as body mass and metabolism, across a wide 
range  of  organisms.    Similar  relations  have  contributed  to  understanding  phenotypic 
variability in populations of bacteria (Balaban et al., 2004) and eukaryotic immune cells 
(Feinerman et al., 2008), the fluctuation-response relationship in bacterial chemotaxis 
(Park et al., 2010), the structural properties of metabolic networks (Jeong et al., 2000), 
growth and gene expression in populations of E. coli (Scott et al., 2010), and epistatic 
interactions between genes in yeast (Velenich and Gore, 2013).  Motivated by the success 
of scaling laws across disciplines, here we set out to identify similar principles that unify 
the description of drug interactions in sensitive and resistant cells.  The discovery of such 
scaling relations could provide a new approach for systematically adapting multi-drug 
treatments to effectively combat drug resistance, even before molecular mechanisms have 
been fully elucidated.   
 
Results 
Drug Interactions Can Change Following Acquisition of Resistance 3 
 
We first asked how acquired drug resistance affects the interactions between two drugs 
observed  initially  in  wild-type,  drug-sensitive  cells.  To  answer  this  question,  we 
measured population growth of a wide range of organisms, including bacteria and human 
cancer cells, in response to drug pairs (Supplemental Information Section I, Tables S1-
S3). We then quantified the nature of drug interaction—synergy or antagonism—in both 
wild type and resistant cells using two standard pharmacology approaches (Figure 1; 
Figure S1). Interestingly, we find that resistance can alter not only the individual drug 
efficacies, but also the interactions between drugs.  That is, two drugs can interact quite 
differently  depending  on  whether  they  are  applied  to  drug  resistant  mutants  or  drug 
sensitive cells (Figures 1, S1). For example, the combination of two anti-cancer agents, 
Gefitinib and 17-AAG, is antagonistic for most dosages in EGFR-mutant non-small cell 
lung cancer (NSCLC) cells, making it an unlikely a priori choice for therapy (Figure 1A).  
However, the same drug pair becomes synergistic for most dosages (Xu et al., 2012) in a 
Gefitinib-resistant mutant (Engelman et al., 2007) (Figure 1A).  On the other hand, in E. 
coli,  the  antagonism  between  some  drug  pairs  is  eliminated  (Figure  1B)  or  reduced 
(Figure 1C) in antibiotic-resistant mutants, but the interactions do not become synergistic.  
A similar decrease in the interactions between antibiotics occurs in vancomycin-resistant 
E. faecalis (Palmer  et  al.,  2011),  where  the  synergy  (Rand  and  Houck,  2004)  in  the 
combination  of  daptomycin  and  ampicillin  is  reduced  in  certain  daptomycin-resistant 
mutants  (Figure  1D).    By  contrast,  in  E.  coli  exposed  to  the  weakly  synergistic 
combination  of  doxycycline  and  erythromycin,  the  drug  pair  becomes  increasingly 
synergistic in some multi-drug resistant mutants (Figure 1E).  We also observe cases 
where  the  drug  interactions  are  not  changed  by  resistance  events.    For  example,  the 
antibiotics  chloramphenicol  and  norfloxacin  show  approximately  the  same  level  of 
antagonism  in  S.  aureus  cells  and  norfloxacin-resistant  mutants.    In  this  case,  the 
mutation  reduces  the  effective  concentration  at  which  norfloxacin  becomes  toxic  but 
otherwise  does  not  modify  the  shape  of  the  cell's  two-drug  response  surface;  similar 
results have been reported for some mutations in E. coli (Chait et al., 2007). In summary, 
we find that resistance can alter drug interactions in multiple different ways, and there is 
no obvious relationship between the interactions observed in sensitive cells and those in 
resistant mutants. 4 
 
 
A Simple Model Can Describe a Wide Range of Two-Drug Response Surfaces 
To establish a relationship between drug interactions before and after the acquisition of 
resistance, we constructed a simple model to quantitatively characterize growth response 
surfaces  to  two  drugs.  Response  surfaces  are  commonly  used  for  quantifying  and 
classifying  the  interactions  between  two  drugs  based  on  measurements  of  cell 
proliferation (Fitzgerald et al., 2006; Greco et al., 1995; Lehar et al., 2008; Lehar et al., 
2007).  However, most models apply to only a subset of all measured response surfaces 
because they are based on simplified enzyme kinetics or are specific to particular drugs 
classes and particular intracellular pathways (Fitzgerald et al., 2006; Greco et al., 1995; 
Lehar et al., 2008; Lehar et al., 2007). To account for different types of response surfaces, 
we used a model of the following multiplicative form, 
 
          !!,! = !!(!!)!!!(!!!""),  (1) 
 
where g1,2 is the growth in the presence of drugs 1 and 2 together, g1 is the growth as a 
function of drug 1 alone, and g2 is the growth as a function of drug 2 alone. D1 is the 
concentration of drug 1, and D2eff  is the effective concentration of drug 2, which accounts 
for interactions between the drugs .  Changing the concentration D2 into D2eff formally 
captures the interaction between the two drugs by allowing the presence of one drug (D1) 
to modify the effective concentration, and hence the toxicity, of the other (D2) according 
to 
          D2eff = D2 (1+C(D1))
-1,  (2) 
Note that D2eff is equal to the concentration D2 modified by a factor (1+C(D1))
-1 that 
depends only on D1. This dependence is governed by the function C(D1), which we call 
the  2-drug  toxicity  function  (see  Supplemental  Information,  Section  II).  The  specific 
definition of this factor is empirical and has been chosen by analogy with simple efflux-
mediated  drug  interactions  (Wood  and  Cluzel,  2012).  The  function  C(D1)  will  prove 
essential  for  establishing  scaling  relationships  between  wild  type  and  mutant  cells.  
Importantly, Equations 1 and 2 allow us to decompose two-drug response surfaces into 
three simpler, one-dimensional "basis functions":  g1(D1), g2(D2), and C(D1).   5 
 
 
We  first  verified  that  this  model  is  sufficiently  general  to  describe,  with  a  minimal 
number of parameters, all experimentally observed response surfaces. Figure 2A shows a 
typical example of a response surface, in this case for E. coli, in the presence of the 
antibiotics  chloramphenicol  and  ciprofloxacin  (for  experimental  details,  see 
Supplemental Information Section I). Strongly antagonistic behavior between these drug 
classes has been linked with a suboptimal ratio of protein to DNA in the cell (Bollenbach 
et al., 2009). Using the measured two-dimensional response surface, we first extracted the 
1-drug toxicity functions (g1 and g2) and then determined the 2-drug toxicity function 
C(D1) empirically from the data. Specifically, we fit the response surface data using the 
two latter equations and an empirical parameterization for C(D1) . We select the best 
parameterization  of  C(D1)  among  a  set  of  11  possibilities  using  Akaike  Information 
Criteria,  a  robust  model  selection  technique  (Supplemental  Information  Section  II). 
Together with equation 1, these three functions (g1, g2, and C(D1)) determine the bacterial 
growth response surface for any concentration of the two drugs (Figure 2, right panel). 
 
The model provides a similarly good description for all the 19 additional drug pairs tested 
(Supplemental  Information  Section  II,  Table  S5),  spanning  a  wide  range  of  response 
surfaces and yielding C(D1) functions with many different shapes (Figure 2B). In some 
mechanistically  tractable  cases,  the  2-drug  toxicity  function  is  constrained  by  the 
intracellular  molecular  pathways  underlying  the  single-drug  and  multi-drug  responses 
(Supplemental  Information  Section  III,  Figure  S2).    For  example,  in  the  multiple 
antibiotic  resistance  (MAR)  system,  C(D1)  is  proportional  to  the  activity  of  the  mar 
promoter  (Figure  S2B;  (Wood  and  Cluzel,  2012)).  More  generally,  the  model 
decomposes two-dimensional response surfaces into three simpler, empirical functions 
that do not require a detailed molecular understanding of the drug interaction or mode of 
action. 
 
The  Decomposition  of  Response  Surfaces  into  Basis  Functions  Reveals  Scaling 
Relationships Between Drug Sensitive and Drug Resistant Cells 
Next, we exploit the decomposition of response surfaces into basis functions to search for 
mathematical relationships between the multi-drug responses of drug-sensitive and drug-6 
 
resistant cells. We hypothesized that certain properties of the basis functions should be 
conserved when bacteria become drug-resistant. Specifically, we postulate that the effect 
of resistance can be: (i) to rescale the concentration of each drug, with the scaling factors 
a1or a2 specific to each mutant, and/or (ii) to change the interaction between drugs by 
rescaling the amplitude of the 2-drug toxicity function C(D1) (Equation 2) by a single 
parameter, a3 (Figure 3). Assumption (i) is consistent with known resistance mechanisms, 
such as up-regulation of efflux pumps (Wood and Cluzel, 2012), enzymatic degradation, 
or target modification, which all reduce effective intracellular concentrations of a drug 
(Chait et al., 2007). Assumption (ii) preserves the shape, but not the magnitude, of the 
2-drug toxicity function C(D1). This assumption stems from the idea that new resistant 
mutants will not fundamentally redefine the strategies that the parent cell has evolved to 
cope with the stress of specific drugs. There should exist, therefore, a hidden symmetry 
unifying  the  responses  of  drug-sensitive  and  drug-resistance  cells.    Under  this 
assumption, however, the two-drug response surface can still change dramatically—for 
example,  from  synergistic  to  antagonistic—when  cells  become  drug  resistant.  This 
change is captured entirely by the scaling factor a3. The hypotheses (i) and (ii) are further 
motivated by results in the well-characterized MAR system (Wood and Cluzel, 2012) and 
by numerical toy models (Supplemental Information section III). If accurate, this model 
predicts  that  it  is  possible  to  unify  the  response  surfaces  of  drug  sensitive  and  drug 
resistant cells through simple scaling relations. Importantly, this scaling approach implies 
that it may be possible to predict the full two-drug response of resistant mutants from a 
small number of measurements when the response of drug-sensitive cells is known. 
 
To  experimentally  test  the  model,  we  isolated  drug-resistant  mutants  of  E.  coli  by 
growing wild type cells for 30 to 60 generations in various inhibitory concentrations of 
chloramphenicol  (Cm)  and  ciprofloxacin  (Cip)  either  together  or  sequentially  (see 
Supplemental Information Section I for experimental details). The concentrations of Cm 
and Cip were chosen along a single contour of constant growth to keep the conditions of 
selection approximately constant for all mutants. We then measured the full response 
surface and extracted the three basis functions describing the effects of the same two 
drugs  (Cm-Cip)  on  these  mutants  (Figures  3A,  S3A-B).  The  collection  of  responses 7 
 
represents a broad range of behaviors, with mutants exhibiting a resistance to Cip and Cm 
that varies by an order of magnitude or more (Figure 3A, top panel).  However, Figure 
3B (bottom panel) demonstrates that these different behaviors can be unified using one 
single set of basis functions, common to all mutants, and three scaling parameters (a1, a2, 
and a3) specific to each mutant, thereby supporting our scaling hypotheses.   
 
Additionally, we found that this scaling approach was valid for a wide range of cells 
across several domains of life, which includes E.coli, E. faecalis, and human cancer cells 
(Figure 3C-E).  In some cases, we observed statistically significant (as measured by a3) 
small changes  in  drug  interaction,  for  example,  from  strongly  antagonistic  to  weakly 
antagonistic  (Figure  3C).  In  other  cases,  scaling  unifies  very  different  phenotypic 
behaviors, such as the synergy and additivity of ampicillin and daptomycin in wild-type 
E. faecalis and a daptomycin-resistant (Dap-C) mutant (Figure 3D; See also Figure 1D). 
Even more surprisingly, scaling laws unify the synergy and antagonism of 17-AAG and 
Gefitinib found in human non-small cell lung cancer (NSCLC) cells and a Gefitinib-
resistant mutant (Figure 3E; see also Figure 1A).  Thus, while response surfaces can 
sometimes  change  markedly  when  resistance  is  acquired,  we  find  that  the  functional 
forms of the underlying basis functions are conserved.   
 
These results suggest that the response surfaces of drug-resistant cells are constrained by 
those  of  the  drug-sensitive  wild  type  cells.    If  true,  one  could  fully  characterize  the 
response surface of a resistant mutant by estimating with only a few measurements the 
scaling parameters a1, a2, and a3, thus eliminating the need for a labor-intensive sampling 
of the entire surface. Because this rescaling procedure requires very few measurements, it 
allows  one  to  infer  behavior  even  in  unsampled  regions  of  dosage  space  (Figure  4, 
schematic). 
 
 
 
 
Scaling Relations Can Be Used To Rapidly Infer Response Surfaces of Resistant Mutants 
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To  examine  if  scaling  relations  can  be  used  to  predict  response  surfaces  of  resistant 
mutants, we first focused on three clinically relevant bacterial species:  S. aureus, E. 
faecalis, and E. coli.  For S. aureus, we measured the full response surface of wild-type 
and  norfloxacin-resistant  cells  for  the  drug  combination  norfloxacin-chloramphenicol, 
which is antagonistic in wild-type cells (Figure 5A, left panel; see also Figure 1F).  Using 
only 5 randomly selected data points, we estimated the scaling parameters and used them 
to infer mutant growth in unsampled regions of dosage space.  The scaling parameters 
reflect slightly increased sensitivity to chloramphenicol (a1>1) and increased resistance to 
norfloxacin (a2<<1). The antagonism between drugs is equal to that in wild type cells (a3 
~ 1, see also Figure 1F), making this example similar to those previously reported in E. 
coli (Figure S3C, (Chait et al., 2007)). 
 
Next, we compared the responses of a daptomycin-sensitive strain and three daptomycin-
resistant strains of E. faecalis (Palmer et al., 2011) to combinations of daptomycin and 
ampicillin (Figures 5B, S4A-B See also Figure 1D). These strains were evolved under 
daptomycin  pressure  and  represent  three  distinct  evolutionary  routes  to  daptomycin 
resistance, each with a unique set of genetic mutations (Palmer et al., 2011). Using the 
wild-type basis functions, we are able to predict the two-drug response for each mutant 
by estimating the parameters a1, a2, and a3. For the ampicillin-daptomycin combination, 
all three mutants demonstrate significant resistance to daptomycin (a1 < 0.02), increased 
sensitivity to ampicillin (a2 > 1), and a drug-drug interaction with slightly (a3 = 0.87, 
Dap-A mutant) or significantly decreased synergy (a3 = 0.05, Dap-C mutant, Figure 5B; 
see also Figure 3D). We also accurately inferred response surfaces for combinations of 
daptomycin and linezolid, an oxazolidinone often used to treat infections of the skin as 
well as pneumonia (Figure S4C-E).   
 
Finally, we tested the scaling hypothesis for two clinically isolated E.coli mutants that 
share a particularly common mechanism of drug resistance:  modification of the drug 
target (Cohen et al., 1989) (748k.01, Figure S4F-G).  Specifically, each strain exhibited 
resistance to DNA synthesis inhibitors (fluoroquinolones) arising from distinct mutations 
in the gene (gyrA) encoding the target topoisomerase (Cohen et al., 1989). In both cases, 
the  3-parameter  scaling  provides  an  excellent  prediction  of  the  response  surfaces  to 9 
 
chloramphenicol  and  ciprofloxacin  (Figure  S4F-G),  and  all  mutants  exhibit  little 
resistance to chloramphenicol (a1 ~ 1), strong resistance to ciprofloxacin (a2 < 0.1), and 
significantly weaker drug-drug suppression (a3 < 1) than in the wild type.  These scaling 
relationships hold as well for multiple E. coli laboratory mutants with evolved resistance 
to  protein  synthesis  inhibitors,  including  doxycycline,  erythromycin,  and 
chloramphenicol (Figure S4H-K; see also Figure 1B, 1E). We also verified the scaling 
relations in a cycloheximide-resistant mutant of the budding yeast S. cerevisiae (Korolev 
et al., 2012) exposed to a combination of antifungal agents (Figure S4L).   
 
We next asked whether the scaling hypothesis applies to drug combinations targeting 
human cancer cells, which possess significantly more genetic complexity and redundancy 
than  microbes.  Figure  5C  shows  the  previously  discussed  Gefitinib/17-AAG 
combination,  where  strong  antagonism  in  the  parental  NSCLC  cells  is  replaced  by 
synergy in the Gefitinib-resistant (GR6) mutant (Engelman et al., 2007).  Remarkably, 
our rescaling approach allows us to predict the mutant response surface for all dosage 
combinations (see also Figure S4N for the same cells with Gefitinib and Paclitaxel). We 
find that there is little resistance to 17-AAG (a1~1) but a significant increase in Gefitinib 
resistance  (a2<<1).  In  addition,  a3  switched  signs  from  positive  to  negative,  which 
accounts for the observed phenotypic change from antagonistic interaction in the parental 
cell line to synergistic interaction in the mutant (recall Figure 1A, Figure 3F). In this case, 
the  synergy  arises  because  17-AAG  inhibits  HSP90,  which  leads  to  decreased  MET 
protein stability (Xu et al., 2012).  The loss of MET, in turn, sensitizes the previously 
resistant cells to Gefitinib.  In terms of our scaling model, the Gefitinib resistance inverts 
the drug-drug coupling effect of 17-AAG on Gefitinib; rather than lowering the Gefitinib 
toxicity, as in drug sensitive cells, the presence of 17-AAG raises the effective Gefitinib 
toxicity in mutant cells.  These results again demonstrate that the response surfaces can 
change markedly following the activation of a resistance event, whereas the functional 
forms  of  the  basis  functions  are  conserved.  From  a  practical  perspective,  the  scaling 
approach  allowed  us  to  rapidly  recognize  the  strong  synergy  between  17-AAG  and 
gefitinib in resistant cells (Figure 5C), thereby identifying a potent therapy despite the 
fact that the drugs are antagonistic in drug-sensitive cells. We also show that the full 10 
 
response surfaces of RAF inhibitor (PLX4720)-resistant melanoma cells to combinations 
of antineoplastic drugs can be predicted using the same approach (Figure S4M).   
 
Scaling Relations Can Be Used To Increase Potency of Drug Combination Targeting 
Cancer Stem Cells 
Recent research has also focused on the general drug resistance that appears in cancer 
stem  cells  (CSCs),  which  are  believed  to  underlie  the  resurgence  of  many  tumors 
following  initial  drug  treatments  (Dick,  2009;  Gupta  et  al.,  2009;  Reya  et  al.,  2001; 
Sachlos et al., 2012). Whereas drug-resistant mutants are typically resistant to a small 
number  of  specific  drugs,  CSCs  are,  in  general,  more  drug  resistant  than  the 
corresponding cancer cells, and the resistance is not driven by mutations (Dick, 2009; 
Gupta et al., 2009; Reya et al., 2001; Sachlos et al., 2012). Because of their simultaneous 
resistance to multiple drugs, CSC’s offer an opportunity to test our scaling approach in 
the context of general drug resistance.   
  We first directly measured the effects of two anti-cancer drugs, Etoposide and 
Fluorouracil, on immortalized mammary epithelial (HMLE) cells and on matched HMLE 
populations enriched for mammary CSCs (Gupta et al., 2009). We found that the effects 
of the individual drugs vary significantly between cells types, with minimum inhibitory 
concentrations (MIC's) increased by factors of approximately 8.5 for Etoposide and 4 for 
5-FU  in  CSCs.    However,  the  effects  of  this  general  drug  resistance  become  more 
complicated when the drugs are combined.  For example, we found that treating the 
HMLE  cells  with  Etoposide  and  5-FU  at  concentrations  of  0.35  mM  and  1.5  mM, 
respectively, results in growth inhibition of about 50% (full growth surface shown in 
Figure 5D, left panel). One would naively expect a similar inhibition (50%) of CSC 
growth when the dosages of each drug are increased to account for increased MICs of the 
drug individually. However, we measured the inhibitory effects of this naïve combination 
therapy to be only about 20%, substantially less than expected.  Interestingly, our scaling 
approach can correctly predict this non-intuitive result with only a few measurements 
(Figure 5D). Furthermore, the scaling relations predict improved therapies.  For example, 
using 8.5 mM of Etoposide alone is correctly predicted to restore growth inhibition to the 
previous 50% levels (Figure 5D, right panel). In this case, we are also able to decrease 
the  total  amount  of  drug  used,  compared  with  the  intuitive  therapy.  Our  prediction 11 
 
quantitatively captures the increased antagonism between 5-FU and Etoposide in CSCs 
and indicates that scaling relations may be applicable to broadly drug-resistant cancer 
stem cells.   
  Overall, we see a wide range of a3 values from experiments in E coli, E. faecalis, 
S. aureus, S. cerevisiae and human cancer cells (Figure S4O), including a3<0 (interaction 
has  changed  from  antagonistic  to  synergistic  or  vice  versa),  0<a3<1  (interaction  has 
decreased in magnitude), and a3>1 (interaction has increased in magnitude). In all cases, 
the mutant response is reconstructed by rescaling the wild type basis functions with only 
three  scaling  parameters  (a1,  a2,  a3)  (Figures  5,  S4A-N).  Therefore,  our  scaling 
hypotheses, which are based on conservation of basis functions, hold for all resistant cells 
characterized in this study. The scaling also correctly preserves the interaction (a3=1) in a 
drug-with-itself mock experiment (Figure S5A-D). 
 
Observed Scaling Relationships are Unlikely to Occur By Chance 
In view of the smoothness of the typical drug-response surfaces, it is tempting to think 
that any two surfaces could perhaps be rescaled one into another. Therefore, it is not a 
priori  clear  whether  the  scaling  relationships  reported  here  reflect  some  underlying 
biological similarity between cellular responses or the scaling relationships are likely to 
exist  between  any  two-dimensional  response  surfaces.  To  explore  this  question,  we 
developed a null model to quantify the probability of observing our scaling results by 
chance in a random ensemble of smooth response surfaces (Supplemental Information 
Section V, Figures S5E-F). This analysis reveals that the reported experimental scaling 
relationships are unlikely to occur by chance (p<0.1 for at least 32 of 42 mutants in the 
study;  Figure  S5E).  We  also  find  that  basis  functions  from  some  drug  pairs  can  be 
rescaled to fit a large number of response surfaces, while basis functions from other drug 
pairs are highly specific to a given drug combination (Figure S5F). Overall, this analysis 
suggests that the reported scaling relationships do not hold for arbitrary response surfaces 
and instead represent an unexpected connection between wild-type and mutant response 
surfaces. In addition, the scaling approach outperforms standard interpolation methods 
for predicting growth in unsampled regions of dosage space (Supplemental Information 12 
 
Section V, Figure S5G-J) and is robust to variations in how the scaling parameters are 
determined (Supplemental Information Section V, Table S7, Figure S5K). 
 
 
Scaling Relations Reflect Species-Specific and Drug-Specific Relationships 
 
To further explore the limits of the observed scaling relationships, we asked whether 
basis  functions  derived  from  one  specific  bacterial  type  could  be  rescaled  to  infer 
response surfaces in other bacterial species. As a consequence of hypothesis (ii) of the 
model, it should be possible to use identical basis functions for closely species related 
because they have most likely evolved similar strategies to cope with chemical stressors. 
To test this idea, we rescaled the wild-type basis functions measured for E. coli (strain 
k01.48)  exposed  to  chloramphenicol  (Cm)  and  ciprofloxacin  (Cip)  in  an  attempt  to 
describe the Cm-Cip response surface in mutants from other bacterial strains. We found 
that scaled versions of the k01.48 Cm-Cip basis provide an excellent description of drug-
resistant mutants from the same strain (Cohen et al., 1989) (k01.48, Figure 6A, red). But 
using the same basis functions yields increasingly poor predictions for mutants of more 
distant E. coli strains (Figure 6A, blue) as well as for cells of distantly related bacteria (E. 
faecalis, Figure 6A, black; S. aureus, Figure 6A, green). Our results suggest that the 
scaling  relationships  may  apply  across  species  of  closely  related  organisms  but,  in 
general, they cannot be used to unify the drug-response of distant species.  
 
Similarly,  we  asked  whether  the  basis  functions  describing  one  drug  pair  could  be 
rescaled to describe the response surface of a different drug pair.  To do so, we used the 
basis functions from the Cm-Cip response surface (E. coli (BW25113)) to rescale the 
response surfaces from other drug pairs in the same strain (Figure 6B). We found that the 
basis functions associated with Cm-Cip provide an excellent model for the response to 
Cm-Ofl, a drug pair with similar modes of action. The same basis also provides a good 
model for some other drug pairs, such as Cm-Linc and Dox-Ofl, while other drug pairs, 
including  Cm-Tmp  and  Ery-Tmp,  cannot  be  well  described  with  the  Cm-Cip  basis. 
Interestingly, the shapes of some sets of basis functions are similar, especially when 
drugs  have  similar  modes  of  action.  These  basis  functions  may  therefore  be  used  to 
complement  existing  strategies  (Yeh  et  al.,  2006)  for  functionally  classifying  drugs 13 
 
because our results indicate that they encode drug-specific information (see also Table 
S6). 
 
Discussion 
We have experimentally shown that the two-drug responses of sensitive and resistant 
cells share common features unified by simple, but general, scaling relations.  We have 
tested these scaling relations using a broad collection drugs, including traditional classes 
of antibiotics (inhibitors of protein synthesis, DNA synthesis, cell wall synthesis, folic 
acid  synthesis),  clinically  relevant  antibiotics  (linezolid  and  daptomycin),  and  drugs 
inducing  general  stress  response  (salicylate).  We  have  also  used  both  classic 
chemotherapy drugs, such as alkylating agents, microtubule inhibitors, and topoisomerase 
inhibitors, as well as targeted therapies. The predictive power of these scaling relations 
has  been  demonstrated  in  a  wide  range  of  mutants  exhibiting  many  resistance 
mechanisms,  including  drug  efflux-mediated  resistance,  target  modification  (e.g. 
fluoroquinolone-resistant E.coli, Figure S4F-G), pathway reactivation (Gefitnib-resistant 
mutant,  Figure  1a,  3e,  5c,  and  PLX4720-resistant  A375,  Figure  S4M),  and  de-
differentiation  (CSC's,  Figure  6a,  6b).  The  scaling  relations,  analogous  to 
phenomenological laws, are not directly noticeable in two-dimensional response surfaces. 
However, when the surfaces are decomposed into three basis functions, the underlying 
symmetry  is  clear:    the  shapes  of  these  functions  do  not  change  when  resistance  is 
acquired. Previous work (Lehar et al., 2007) suggests that interactions between inhibitors 
of a biochemical network reflect the underlying network topology. In our model, these 
network properties seem to manifest themselves as 2-drug toxicity functions with specific 
functional forms (Supplemental Information Section III). Our primary experimental result 
is  that,  surprisingly,  these  shapes  are  not  fundamentally  altered  when  cells  become 
resistant, even when the response surfaces of drug-sensitive and drug-resistant cells differ 
dramatically.   
 
  From  a  molecular  perspective,  these  scaling  properties  may  arise  because 
resistance is conferred by relatively small genetic changes, and not by any major re-
wiring of intracellular networks that govern the global response to drugs.  Therefore, the 14 
 
mutant response is inherently constrained by that of the drug-sensitive parental cells.  
These scaling relations are evident in genetically similar cells, but they break down when 
applied  across  evolutionary  distant  species.  Overall,  we  found  these  relationships 
between drug-sensitive and drug-resistant cells to be robust within many organisms, both 
prokaryotic  and  eukaryotic,  and  within  many  classes  of  drugs.  Therefore,  scaling 
relationships  may  reduce  the  complexity  of  drug  resistance  studies  by  unifying  the 
responses of drug resistant mutants with that of drug-sensitive cells even before specific 
biochemical mechanisms have been elucidated. 
 
Experimental Procedures 
Cell lines, strains, and reagents.   
Bacteria 
A table of bacterial strains is given in Table S1. 
Mammalian Cells 
HCC827  parental  (WT)  and  Gefitinib-resistant  (GR6)  cells,  the  latter  of  which  were 
evolved by stepwise selection in increasing concentrations of Gefitnib, were obtained 
from J. Engelman (Massachusetts General Hospital) and grown in RPMI with 10% fetal 
bovine  serum  (FBS)  and  1%  penicillin/streptomycin.    HMLE  cells  stably  expressing 
lentiviral  short  hairpin  RNAs  (shRNA)  against  GFP  (control)  and  E-Cadherin  were 
obtained from P. Gupta (Whitehead Institute for Biomedical Research) and grown in 
media consisting of equal parts (1) complete MEGM media (Lonza) and (2) DMEM with 
10%  fetal  bovine  serum  (FBS)  and  1%  penicillin/streptomycin  (Gupta  et  al.,  2009).  
A375 parental (WT) cells were obtained from ATCC and grown in RPMI with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin.  PLX4720-resistant A375 cells were 
engineered by stably overexpressing the kinase C-RAF, which can confer resistance to 
PLX4720 by overriding B-RAF dependence (Montagut et al., 2008).  C-RAF-expressing 
lentiviruses were produced as previously described (Johannessen et al., 2010; Wood et 
al., 2012).  A375 parental cells were infected at a 1:10 dilution of virus in 6-well plates in 
the  presence  of  7.5  µg/ml  polybrene  and  centrifuged  at  1200g  for  1  hour  at  37°  C. 
Twenty-four  hours  after  infection  blasticidin  (10  µg/ml)  was  added  and  cells  were 15 
 
selected for 72 hours, after which blasticidin was removed and growth inhibition assays 
were performed.   
!
Drugs 
Drug solutions were made from solid stocks (Table S2). All antibiotic stock solutions 
were stored in the dark at -20◦ C in single-use daily aliquots. All drugs were thawed and 
diluted in sterilized media for experimental use.  
 
Growth Inhibition Assays 
Growth Assay for Bacteria 
We inoculated media (LB for E. coli, TSB for S. aureus, BHI for E. faecalis) from a 
single colony and grew the cells overnight  (12 h at 30°C with shaking at 200 rpm for E. 
coli, S. aureus; no shaking for E. faecalis). Following overnight growth, stationary phase 
cells were diluted (~5000 fold for E. coli, S. aureus; ~1000 fold for E. faecalis) in media. 
Following the initial dilution, S. aureus and E. faecalis were grown in drug free media for 
1 hour prior to adding drugs and transferring to 96 well plates.  We transferred E. coli to 
96-well plates (round bottom, polystyrene, Corning) immediately following dilution.  For 
each experiment, we set up a two-dimensional matrix of 1 or 2 drug combinations in each 
of four 96-well plates (165-190 µl media per well). For the remainder of the experiment 
after the addition of drugs  (~10-12 h), cells were grown at 30°C (with shaking at 1000 
rpm on four identical vibrating plate shakers for E. coli; no shaking for E. faecalis). A600 
(absorbance at 600 nm, proportional to optical density OD) was measured at 15-25 min 
intervals  (with  one  exception;  see  below)  using  a  Wallac  Victor-2  1420  Multilabel 
Counter  (PerkinElmer) combined with an automated robotic system  (Twister II, Caliper 
Life Sciences) to transfer plates between shakers and the reader.  Growth rates in bacteria 
were determined by fitting background-subtracted growth curves (A600 vs. time) in early 
exponential  phase    (approximately  0.01  <  A600  <0.1)  to  an  exponential  function  
(MATLAB 7.6.0 curve fitting toolbox, The Mathworks). For S. aureus with Nor-Cm 
(Figure  5),  effective  exponential  growth  rates  were  estimated  using  background 
subtracted A600 measurements at times t = 2 hours and t = 6 hours; true exponential 
growth curves are therefore not required for this particular assay, which is instead similar 16 
 
to traditional viability assays that compare cell number at the end of the experiment (see 
mammalian growth assays, below).  Growth rates were normalized by the growth of cells 
in the absence of drugs.  Error bars, unless otherwise noted, are taken to represent +/- one 
standard error of the fitted parameter.   
 
Growth assay for Mammalian Cells 
Cells  were  trypsinized,  counted,  and  seeded  into  96-well  plates  at  2,500  cells/well.  
Twenty-four later, DMSO or concentrated dilutions of indicated drugs (in DMSO) were 
added to cells (1:1,000 in standard media) to yield the indicated final drug concentrations. 
Cell  viability  was  measured  4  days  after  drug  addition  using  the  Cell  Titer  Glo® 
luminescent  viability  assay  (Promega).  Viability  was  calculated  as  the  percentage  of 
control (untreated cells) after background subtraction. Three replicates were performed 
for each drug/concentration.  
 
Evolved Drug Resistant Mutants in E. coli and S. aureus 
Drug resistant E. coli mutants were evolved under conditions in Table S3. S. aureus 
norfloxacin  resistant  mutants  were  isolated  on  TSA  (Trypric  soy  agar,  BD)  plates 
containing 4 ug/ml Nor, followed by spreading of overnight culture of Newman strain. 
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Figure captions 
 
Figure 1:  Resistance that either alters or conserves interactions between drugs in 
prokaryotic and eukaryotic cells 
 
Heat maps quantify the drug interaction and classify it as synergistic or antagonistic 
across a range of active concentrations for both wild type and mutant cells.  To quantify 
the drug interaction at each point on the response surface, we define the interaction 
parameter I = log2(g12 - g1 g2 + 1), which is positive (blue) for antagonistic, negative (red) 
for synergistic interactions (Bollenbach and Kishony, 2011), and 0 when there is no 
interaction (g12 = g1 g2, consistent with Bliss independence).  In addition to modifying the 
resistance of cells to one or more drugs, resistance events can sometimes modify the 
interactions between drug pairs.  See Figure S1 for an alternative quantification of drug 
interactions. We note that because mutants in this study are resistant to at least one drug, 
we must use higher drug concentrations for the mutant cells to obtain growth reduction. 
However, we estimated the drug interactions over concentration ranges that yield growth 
reduction in mutant approximately similar to that of wild-type cells (Figure S1).  Drug 
concentrations are given in units of µg/ml unless otherwise noted. 
 
A.  Gefitinib resistance in non-small cell lung cancer (NSCLC) cells changes the 
interaction between 17-AAG and gefitinib from strongly antagonistic (suppressive) to 
synergistic.  Units of [17-AAG] are nM and [gefitinib] are µM. 
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B.  Chloramphenicol resistance in E. coli changes the interaction between salicylate and 
chloramphenicol from strongly antagonistic (suppressive) to additive / weakly 
synergistic. 
 
C.  Chloramphenicol and ciprofloxacin resistance in E. coli weakens the strongly 
antagonistic (suppressive) interaction between chloramphenicol and ciprofloxacin, but 
does not eliminate the antagonism.  Units of [ciprofloxacin] are ng/ml. 
 
D.  Daptomycin resistance in E. faecalis reduces the strongly synergistic interaction 
between ampicillin and daptomycin.   
 
E.  Erythromycin and doxycycline resistance in E. coli increases the synergistic 
interaction between the two drugs.   
 
F.  Norfloxacin resistance in S. aureus does not change the interaction between 
chloramphenicol and norfloxacin.   
 
Figure 2:  Characterization of bacterial response to a pair of drugs using a set of three 
unique basis functions.   
 
A.  Experimental heat map of growth rate relative to that of untreated cells in response to 
a pair of drugs  (chloramphenicol, Cm, and ciprofloxacin, Cip, left).  Red is maximum 
growth,  blue  is  no  growth.    See  Supplemental  Information  Section  I  for  estimate  of 
uncertainty in growth rate.  [Cm] units are µg/ml, [Cip] units are ng/ml.  See related 
Figure S2. 
 
Drug 1 toxicity  (middle top), drug 2 toxicity  (middle center), and  2-drug toxicity 
function (C(D1), middle bottom). The 1-drug toxicity functions are modelled using the 
Hill form common in pharmacology, with Ki the concentration of drug i  (for i=1,2) at 
which the effect is half maximal (also known as the IC50), and ni the Hill coefficient 
describing the slope of the response.  The function C(D1) is an empirically determined 19 
 
function that captures the effect of drug 1 (chloramphenicol) on drug 2 (ciprofloxacin) 
(Equation 2). It is fit directly from data and has the following intuitive interpretation: 
C(D1)=0  when  drug  1  does  not  alter  the  effect  of  drug  2,  while  C(D1)>0  indicates 
antagonistic  interaction  and  C(D1)<0  indicates  a  synergistic  interaction.  The  1-drug 
toxicity  functions  along  with  C(D1)  accurately  describe  the  entire  two-dimensional 
response surface (right).  Circles: experimental measurements; solid lines: nonlinear fits 
to functional forms in A; error bars: +/- one standard error of the growth rate estimate 
(Supplemental Information, Section II). The responses to all 19 drug pairs tested are well 
described by unidirectional 2-drug toxicity functions (Table S5, Figure S2).   
 
B.  Example two drug toxicity functions C(D) for six different drug pairs. For example, 
“C(D) for Tmp” (first panel) describes the effects of chloramphenicol on trimethoprim 
(Tmp).    Concentrations  are  measured  in  units  of  minimum  inhibitory  concentration 
(MIC) = Ki for each drug. Ofl, ofloxacin; Tet, tetracycline; Ery, erythromycin. 
 
 
Figure 3:  Single drug toxicity functions and coupling functions (D2,eff/D2) for drug-
resistant mutants can be rescaled to match those in parental E. coli, E. faecalis, and 
non-small cell lung cancer (NSCLC) cells. 
 
A.  Single drug toxicity functions (top left, top center) and two drug toxicity functions  
(top  right)  for  18  mutant  strains  isolated  by  selection  in  chloramphenicol  (Cm)  and 
ciprofloxacin  (Cip)  at  various  doses    (Table  S3,  Figure  S3).  Each  color  /  marker 
combination represents a single mutant. Drug concentrations are in units of µg/ml for 
chloramphenicol (323 g/mol) and ng/ml for ciprofloxacin (331 g/mol).  C(D) functions 
are constructed point-by-point from raw growth data (Supplemental Information, Section 
II).  
 
B. 1-drug toxicity functions (bottom left, bottom center) and 2-drug toxicity functions 
(bottom right) for all mutant strains are simple re-scalings of the corresponding functions 
in the wild type cells  (Supplemental Information, Section II). A set of three scaling 20 
 
parameters, (a1, a2, a3), provide a set of coordinates that define each mutant.  Specifically, 
mutant 1-drug and 2-drug toxicity functions are obtained from those of wild type cells by 
applying the following transformations 
 
D1 → D1'= a1D1
D2 → D2'= a2D2
C →C'= a3C
 
 
where a1, a2, and a3 are scaling parameters describing the change in resistance to drug 1, 
the change in resistance to drug 2, and the change in the amplitude of C(D1), respectively, 
in the resistant mutant.  Solid line, bottom panels: single toxicity functions (left and 
center panel) and two drug toxicity function (right panel) that best describe rescaled data.  
 
C.-E. Examples of rescaling the amplitude of C(D1) to demonstrate the scaling relations 
in drug-sensitive and drug-resistant cells.   Left panels:  C(D1) functions for wild-type 
(filled circles) and drug-resistant (open circles) cells.  Right panels:  C(D1)  functions for 
wild-type (filled circles) and drug-resistant (open circles) cells following a rescaling of 
the amplitude by a3.  Panel D shows rescaling of WT 2-drug toxicity (black) Dap C 
mutant (Table S1).  Drug concentrations are in units of µg/ml for chloramphenicol (323 
g/mol), dapatomycin (1619 g/mol), and ampicillin (349 g/mol), ng/ml for ciprofloxacin 
(331 g/mol), µM for gefitinib (446 g/mol), and nM for 17-AAG (586 g/mol). 
 
 
Figure 4:  Method for inferring response surfaces of drug-resistant mutants from 
response surfaces of wild type cells. 
The two-drug response surfaces of wild-type (drug sensitive) cells can be used to infer 
the responses of drug resistant mutants.  First, one must extract the 3 basis functions 
describing the wild type surface (Figure 2).  Second, one can estimate the scaling 
parameters a1, a2, and a3 using a small number of measurements of the mutant response 
(left) and then fully reconstruct the response surfaces for each mutant (right). 
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Figure 5:  Rescaling parameters predict the response of resistant mutants to drug 
combinations in unsampled regions of dosage space.   
 
Predicting  of  the  response  of  resistant  mutants  to  a  two-drug  combination  requires 
estimation of only three scaling parameters if the wild-type two-drug response is known. 
(see  Figure  4).      The  responses  of  resistant  mutants  to  each  of  three  two-drug 
combinations (chloramphenicol-norfloxacin in S. aureus (A), ampicillin-daptomycin in 
E. faecalis (B), and gefitinib and 17-AAG in NSCLC cells (HCC827) (C) are predicted 
using scaling parameters estimated using the wild-type basis functions and 5 randomly 
selected measurements of the mutant's growth rate.  Similarly, the responses of drug 
resistant cancer stem cells to etoposide and 5-FU are predicted using scaling parameters 
estimated  using  the  basis  functions  from  parental  cells  and  5  randomly  selected 
measurements of the mutant's growth rate.  The parameters (a1, a2, a3) describing the 
mutants, along with standard errors, are given by A. (1.37±0.03, 0.10±0.002) (a3 not 
needed);  B.  (0.88±0.02,  0.017±0.0005,  0.53±0.06);  C.  (a1,  a2,  a3)  =  (0.9±0.05, 
0.0043±0.0002, -0.22±0.02). Left panels: heat map of relative growth rate in wild type 
cells and relative growth rates for 5 randomly chosen dosages in the mutant cells.  Right 
panel, large figure: comparison of experiment and prediction for each drug dosage in the 
mutant cells. Error bars: +/- standard error of prediction. Inset:  Histograms of root mean 
squared  error  (RMSE)  of  the  predicted  two-dimensional  mutant  growth  surfaces 
constructed from 2500 independent trials.  In each trial, the entire mutant growth surface 
is predicted using five randomly selected data points on the mutant two-drug surface.  
Right panels:  heat maps of relative growth rate for mutant from experiment (top) and 
prediction (bottom).  Black lines show a single contour of constant growth estimated by 
smoothing the growth surface using cubic spline interpolation (csaps function in Matlab). 
Different contour shapes in wild type and mutant cells (panels B, C and D) illustrate that 
drug interactions have changed (see also Figures 1, S1). Drug concentrations are µg/ml 
for all drugs except 17-AAG (nM), gefitinib (µM), Etoposide (µM), and 5-FU (µM).  See 
also related Figure S4. 22 
 
 
 
Figure 6:  Scaling relations hold across related species or drug classes 
A.  The basis functions for chloramphenicol (Cm) and ciprofloxacin (Cip) in drug-
sensitive E.coli (k01.48) are rescaled to fit Cm-Cip response surfaces measured in drug-
resistant mutants from the same strain (red) as well as mutants from E.coli BW25113 
(blue), E. faecalis (black), and S. aureus (green).  Deviation from perfect model is 
defined as 1- R
2, where the coefficient of determination, R
2, is defined as R
2 = 1-SSerr / 
SStot with SSerr the residual sum of squares between model and data and SStot the total 
sum of squares (proportional to the variance of the experimental measurements. 
Schematic phylogenetic tree is plotted below the horizontal axis.    
 
B.   The basis functions for chloramphenicol (Cm) and ciprofloxacin (Cip) in drug-
sensitive E.coli (BW25113) are rescaled to fit response surfaces to other drug pairs in the 
same strain.  Deviation from perfect model is defined as in A.   
 
See also Figure S5 for more detailed statistical analysis. 
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